title: Prologue: 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
abstract: The 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in Stockholm, Sweden, and attended by rheumatologists, dermatologists, and representatives of biopharmaceutical companies and patient groups. In this prologue, we introduce the articles that summarize that meeting. As in previous years, GRAPPA members held a Trainees Symposium, providing an opportunity for trainees to discuss their research in psoriatic disease with experts in the field. Two dermatology sessions were held: an update on the International Dermatology Outcome Measures group; and a description of a new tool, the Comprehensive Assessment of the Psoriasis Patient, to more accurately assess the full burden of plaque psoriasis and its subtypes. Four distinct plenary sessions were held to update members on the status of the Outcome Measures in Rheumatology (OMERACT) initiative. GRAPPA's patient research partners discussed their 2 years of involvement in GRAPPA activities and were active in several sessions before and during the 2015 annual meeting. New work was presented toward developing a patient-reported instrument to measure flare in psoriatic disease, and the status of GRAPPA's multiple research and continuing education programs in psoriasis and PsA was summarized. Finally, a Presidential Round Table was held in which the past, current, and incoming presidents reflected on GRAPPA's history and provided insights about its future.
authors.affiliation: From the Division of Dermatology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland; The University of Toronto; Krembil Research Institute; and the Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; and Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.W.H. Boehncke, MD, Division of Dermatology, Geneva University Hospital, Department of Pathology and Immunology, University of Geneva, President, GRAPPA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, University Health Network; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust. wolf-henning.boehncke@hcuge.ch.
authors.forename: Wolf-Henning
authors.initials: WH
authors.lastname: Boehncke
authors.affiliation: From the Division of Dermatology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland; The University of Toronto; Krembil Research Institute; and the Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; and Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.W.H. Boehncke, MD, Division of Dermatology, Geneva University Hospital, Department of Pathology and Immunology, University of Geneva, President, GRAPPA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, University Health Network; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.
authors.forename: Dafna D
authors.initials: DD
authors.lastname: Gladman
authors.affiliation: From the Division of Dermatology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland; The University of Toronto; Krembil Research Institute; and the Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; and Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK.W.H. Boehncke, MD, Division of Dermatology, Geneva University Hospital, Department of Pathology and Immunology, University of Geneva, President, GRAPPA; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, University Health Network; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust.
authors.forename: Philip S
authors.initials: PS
authors.lastname: Helliwell
mesh_terms: D015535:Arthritis, Psoriatic; D006801:Humans; D009938:Organizations; D011565:Psoriasis; D012106:Research; D012219:Rheumatology / Q000193:education*; D013548:Sweden; D003226:Congresses as Topic
keywords: COMPREHENSIVE ASSESSMENT OF THE PSORIASIS PATIENT; FLARE; OMERACT; OUTCOME MEASURES; PSORIASIS; PSORIATIC ARTHRITIS